netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Bendamustine found 9 matches
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Bendamustine Malignant disease and immunosuppression - Alkylating drugs - 08.01.01
  Obinutuzumab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Polatuzumab vedotin  (Polivy®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Rituximab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (July 2017): Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation (08.01.01)
link in drug section MHRA Drug Safety Update (March 2021): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) (08.01.01)
link in drug section NICE TA216: Bendamustine for CLL (08.01.01)
link in drug section NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (08.02.03)
link in drug section NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (08.01.05)


 
netFormulary